**Core Concept:** P2Y12 receptors are a subgroup of P2Y purinoceptors, which are G-protein-coupled receptors that are activated by ADP (adenosine diphosphate). These receptors play a crucial role in platelet aggregation, and are essential for understanding the pharmacodynamics of antiplatelet drugs like clopidogrel, prasugrel, and ticagrelor. P2Y12 receptors are predominantly expressed on platelets, endothelial cells, and neurons.

**Why the Correct Answer is Right:** Drugs that do not act on P2Y12 receptors would not inhibit platelet aggregation effectively, as they would not interfere with the ADP signaling pathway. As a result, these drugs would not exert their antiplatelet effects, potentially increasing the risk of thrombotic events.

**Why Each Wrong Option is Incorrect:**
A. P2Y1 receptors: P2Y1 receptors are different from P2Y12 receptors, and drugs targeting P2Y1 receptors do not inhibit platelet aggregation. For example, U46619 is a potent agonist of both P2Y1 and P2Y12 receptors, but its effect on P2Y12 receptors is significantly greater than its effect on P2Y1 receptors.

B. P2Y12 receptors are not the sole target for antiplatelet drugs: Although these drugs primarily target P2Y12 receptors, other platelet receptors (e.g., thromboxane A2 receptors) are involved in platelet aggregation as well. However, drugs like aspirin inhibit the cyclooxygenase pathway, which indirectly affects platelet aggregation by reducing thromboxane A2 production.

C. P2Y1 receptors are not the only target for antiplatelet drugs: Similar to option B, antiplatelet drugs primarily target P2Y12 receptors, but they also affect other platelet receptors to some extent.

D. P2Y1 receptors are not the sole target for antiplatelet drugs: As mentioned earlier, antiplatelet drugs primarily target P2Y12 receptors, but they also affect other platelet receptors to some extent.

**Clinical Pearl:** In clinical practice, it is crucial for healthcare professionals to understand the pharmacodynamics of antiplatelet drugs to ensure optimal patient management and minimize the risk of bleeding complications.

**Correct Answer:** D. P2Y1 receptors: Antiplatelet drugs, like aspirin and clopidogrel, primarily target P2Y12 receptors but also affect P2Y1 receptors to some extent, as well as thromboxane A2 receptors. By inhibiting these receptors, these drugs help to prevent platelet aggregation and reduce the risk of cardiovascular events in patients with acute coronary syndromes, peripheral arterial disease, and cerebrovascular disease.